BR112013033916A2 - combinação sinérgica de um anticorpo específico para cd19 e uso de um anticorpo - Google Patents

combinação sinérgica de um anticorpo específico para cd19 e uso de um anticorpo

Info

Publication number
BR112013033916A2
BR112013033916A2 BR112013033916A BR112013033916A BR112013033916A2 BR 112013033916 A2 BR112013033916 A2 BR 112013033916A2 BR 112013033916 A BR112013033916 A BR 112013033916A BR 112013033916 A BR112013033916 A BR 112013033916A BR 112013033916 A2 BR112013033916 A2 BR 112013033916A2
Authority
BR
Brazil
Prior art keywords
antibody
synergistic combination
specific
specific antibody
synergistic
Prior art date
Application number
BR112013033916A
Other languages
English (en)
Other versions
BR112013033916B1 (pt
Inventor
Amersdorffer Jutta
Rojkjaer Lisa
Winderlich Mark
Steidl Stefan
Krohn Susanne
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of BR112013033916A2 publication Critical patent/BR112013033916A2/pt
Publication of BR112013033916B1 publication Critical patent/BR112013033916B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
BR112013033916-0A 2011-08-16 2012-08-14 Uso de um anticorpo específico para cd19 BR112013033916B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660.5 2011-08-16
EP11177660 2011-08-16
US61/523,862 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Publications (2)

Publication Number Publication Date
BR112013033916A2 true BR112013033916A2 (pt) 2017-11-28
BR112013033916B1 BR112013033916B1 (pt) 2022-11-16

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033916-0A BR112013033916B1 (pt) 2011-08-16 2012-08-14 Uso de um anticorpo específico para cd19

Country Status (23)

Country Link
US (2) US20140227277A1 (pt)
EP (2) EP4083071A3 (pt)
JP (1) JP6114273B2 (pt)
KR (3) KR20200060779A (pt)
CN (1) CN103703027B (pt)
AU (1) AU2012296905B2 (pt)
BR (1) BR112013033916B1 (pt)
CA (1) CA2841738C (pt)
DK (1) DK2744826T3 (pt)
ES (1) ES2909720T3 (pt)
HR (1) HRP20220224T1 (pt)
HU (1) HUE058855T2 (pt)
IL (1) IL230295B (pt)
LT (1) LT2744826T (pt)
MX (1) MX353589B (pt)
PL (1) PL2744826T3 (pt)
PT (1) PT2744826T (pt)
RS (1) RS63121B1 (pt)
RU (1) RU2664462C9 (pt)
SG (1) SG10201606788VA (pt)
SI (1) SI2744826T1 (pt)
WO (1) WO2013024095A1 (pt)
ZA (1) ZA201401835B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
CN106794231A (zh) * 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
WO2016189014A1 (en) 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
IL257345B2 (en) * 2015-08-21 2023-03-01 Morphosys Ag Combinations and their uses
CN115932265A (zh) * 2016-05-30 2023-04-07 莫佛塞斯公司 预测cd19抗体治疗在患者中的治疗益处的方法
LT3532098T (lt) * 2016-10-28 2021-06-25 Morphosys Ag Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
FI3630177T3 (fi) * 2017-05-31 2023-10-18 Morphosys Ag Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US11852A (en) 1854-10-31 Abraham bassford
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
BR9913645A (pt) * 1998-08-11 2001-09-25 Idec Pharma Corp Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
PT1194167E (pt) 1999-06-09 2009-10-23 Immunomedics Inc Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
ES2307832T3 (es) 2001-12-03 2008-12-01 Amgen Fremont Inc. Clasificacion de anticuerpos basada en las caracteristicas de union.
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
JP2009521912A (ja) * 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
ME01786B (me) * 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
PL2066349T3 (pl) 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CA2702555A1 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
AU2010215239A1 (en) 2009-02-23 2011-09-15 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2010151341A1 (en) 2009-06-24 2010-12-29 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
SG178322A1 (en) * 2009-08-14 2012-03-29 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
KR20120099715A (ko) * 2009-11-06 2012-09-11 인피니티 파마슈티칼스, 인코포레이티드 헷지혹 경로 억제제의 경구용 포뮬레이션

Also Published As

Publication number Publication date
ES2909720T3 (es) 2022-05-10
MX353589B (es) 2018-01-19
JP2014525925A (ja) 2014-10-02
DK2744826T3 (da) 2022-03-28
KR20140071368A (ko) 2014-06-11
US20140227277A1 (en) 2014-08-14
HUE058855T2 (hu) 2022-09-28
PT2744826T (pt) 2022-05-19
RU2664462C9 (ru) 2018-09-28
EP2744826B1 (en) 2022-02-09
KR102117202B1 (ko) 2020-06-01
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
RU2664462C2 (ru) 2018-08-17
IL230295B (en) 2018-03-29
EP4083071A2 (en) 2022-11-02
KR20200060779A (ko) 2020-06-01
RS63121B1 (sr) 2022-05-31
RU2014103490A (ru) 2015-09-27
US20200352975A1 (en) 2020-11-12
ZA201401835B (en) 2015-06-24
HRP20220224T1 (hr) 2022-04-29
CN103703027B (zh) 2018-01-12
AU2012296905B2 (en) 2017-01-05
NZ617771A (en) 2016-01-29
BR112013033916B1 (pt) 2022-11-16
JP6114273B2 (ja) 2017-04-12
KR20190094478A (ko) 2019-08-13
EP2744826A1 (en) 2014-06-25
CA2841738A1 (en) 2013-02-21
WO2013024095A1 (en) 2013-02-21
EP4083071A3 (en) 2023-02-22
CA2841738C (en) 2022-12-06
LT2744826T (lt) 2022-04-25
CN103703027A (zh) 2014-04-02
PL2744826T3 (pl) 2022-05-30
SI2744826T1 (sl) 2022-05-31

Similar Documents

Publication Publication Date Title
BR112013033916A2 (pt) combinação sinérgica de um anticorpo específico para cd19 e uso de um anticorpo
CO6801796A2 (es) Composiciones de tratamiento de pozo de liberación retardada para uso en fluídos de tratamiento de pozo
CO6801647A2 (es) Formulación para anticuerpo anti-α4β7
CO6801648A2 (es) Formulación para anticuerpo anti-α4β7
BR112014000260A2 (pt) composto, e, uso de um composto
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
CO7010785A2 (es) Anticuerpos específicos para trop-2 y sus usos
CO6870005A2 (es) Composición anti-cgrp y uso de las mismas
CO7020870A2 (es) Anticuerpos anti-htra1 y métodos de uso
BR112015013722A2 (pt) sistemas adaptativos de apoio de braço e métodos para uso
BR112014018136A2 (pt) anticorpos ou uso e método para determinar
BR112012021498A2 (pt) ariltriazolonas ligadas a bisaril e seu uso
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
BR112013018656A2 (pt) sistemas e métodos para maximização de uso de amostra
CO6821883A2 (es) Nuevos moduladores y métodos para su uso
BR112014005887A2 (pt) dispositivo de catraca para uma tira; e uso do dispositivo de catraca
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
CO6920293A2 (es) Compuestos antibaterianos y método para su uso
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
BR112014012590A2 (pt) anticorpos anti-cd98 e métodos de uso dos mesmos
BR112013015378A2 (pt) misturador dinâmico e seu uso
BR112013029206A2 (pt) composto, e, uso de um composto
BR112013010272A2 (pt) métodos analíticos e arranjos para uso nos mesmos
BR112013032360A2 (pt) compostos inibidores de glioblastoma e seu uso
BR112014007641A2 (pt) uso de um biocida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: MORPHOSYS AG. (DE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/08/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.